Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | KDR | P35968 | 3/20 | 0.55 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.55 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.55 |
| ▸ | RAF1 | P04049 | 5/20 | 0.54 |
| ▸ | BRAF | P15056 | 4/20 | 0.54 |
| ▸ | CHEK2 | O96017 | 6/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.48 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.48 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.48 |
| ▸ | TEK | Q02763 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4173612 | 0.89 | RAF1 (0.55) | POLBKDRCSNK1A1CSNK1DRAF1 | |
| SCHEMBL5733146 | 0.86 | KDR (0.58) | POLBKDRCSNK1A1CSNK1DRAF1 | |
| SCHEMBL5733440 | 0.82 | KDR (0.56) | KDRCSNK1A1CSNK1DRAF1BRAF | |
| SCHEMBL13906245 | 0.81 | KDR (0.59) | POLBKDRCSNK1A1CSNK1DRAF1 | |
| SCHEMBL4158747 | 0.81 | KDR (0.59) | KDRCSNK1A1CSNK1DRAF1BRAF | |
| SCHEMBL13906239 | 0.81 | KDR (0.54) | POLBKDRCSNK1A1CSNK1DRAF1 | |
| SCHEMBL2931563 | 0.81 | POLB (0.69) | POLBKDRCHEK2PIK3CAAKR1C3 | |
| SCHEMBL2931483 | 0.81 | POLB (0.85) | POLBRAF1CHEK2PIK3CAAKR1C3 | |
| SCHEMBL2931923 | 0.79 | AKR1C3 (0.57) | POLBPIK3CAAKR1C3CSNK2A2CSNK2B | |
| SCHEMBL4161824 | 0.79 | CSNK1D (0.80) | KDRCSNK1A1CSNK1DRAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082404-A1 | BENZIMIDAZOLES | MERCK PATENT GMBH (DE) | 2009-03-26 | — | — | US | claimed |
| US-7470702-B2 | Benzimidazoles | MERCK PATENT GMBH (DE) | 2008-12-30 | — | — | US | claimed |
| US-20070066660-A1 | Benzimidazolyl derivatives | MERCK PATENT GMBH (DE) | 2007-03-22 | — | — | US | claimed |
| EP-1675849-A1 | BENZIMIDAZOLYL DERIVATIVES | MERCK PATENT GmbH (DE) | 2006-07-05 | — | — | EP | claimed |
| WO-2005042520-A1 | BENZIMIDAZOLYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2005-05-12 | — | — | WO | claimed |
| US-20090082404-A1 | BENZIMIDAZOLES | MERCK PATENT GMBH (DE) | 2009-03-26 | — | — | US | disclosed |
| US-20090082404-A1 | BENZIMIDAZOLES | MERCK PATENT GMBH (DE) | 2009-03-26 | — | — | US | disclosed |
| US-20090082404-A1 | BENZIMIDAZOLES | MERCK PATENT GMBH (DE) | 2009-03-26 | — | — | US | disclosed |
| US-7470702-B2 | Benzimidazoles | MERCK PATENT GMBH (DE) | 2008-12-30 | — | — | US | disclosed |
| US-7470702-B2 | Benzimidazoles | MERCK PATENT GMBH (DE) | 2008-12-30 | — | — | US | disclosed |
| US-7470702-B2 | Benzimidazoles | MERCK PATENT GMBH (DE) | 2008-12-30 | — | — | US | disclosed |
| US-20070066660-A1 | Benzimidazolyl derivatives | MERCK PATENT GMBH (DE) | 2007-03-22 | — | — | US | disclosed |
| US-20070066660-A1 | Benzimidazolyl derivatives | MERCK PATENT GMBH (DE) | 2007-03-22 | — | — | US | disclosed |
| US-20070066660-A1 | Benzimidazolyl derivatives | MERCK PATENT GMBH (DE) | 2007-03-22 | — | — | US | disclosed |
| EP-1675849-A1 | BENZIMIDAZOLYL DERIVATIVES | MERCK PATENT GmbH (DE) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005042520-A1 | BENZIMIDAZOLYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082404-A1 | BENZIMIDAZOLES | TIE1, KDR, FLT1 | POLB 2308/4885KDR 2/4885CSNK1A1 2182/4885 |
| US-20070066660-A1 | Benzimidazolyl derivatives | TIE1, ECE2, ABL1 | POLB 1670/4885KDR 5/4885CSNK1A1 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.